Vanda Pharmaceuticals Inc.
VNDA
|
$5.17
4.02%
1.8M
|
Health Technology
(0.0% 1d) (37.9% 1m) (-15.3% 1y) (0.0% 2d) (0.0% 3d) (29.1% 7d) (Infinity% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 297,468,870
http://www.vandapharma.com
Sec Filling | Patents | 284 employees
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
dermatitis schizophrenia nervous system atopic dermatitis
Drugs
Fanapt (iloperidone)Hetlioz (tasimelteon)
Hetlioz LQ (tasimelteon)
add to watch list Paper trade email alert is off
Press-releases
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
Published: 2024-04-17 (Crawled : 13:00) - prnewswire.com
VNDA | $5.17 4.02% 1.8M
|
Health Technology
|
| O: 35.5%
H: 4.61%
C: -3.32%
unsolicited pharmaceuticals
Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
MC | $51.32 0.69% 240K
|
Finance
|
| O: 0.56%
H: 0.8%
C: -0.41%
VNDA | $5.17 4.02% 1.8M
|
Health Technology
|
| O: 35.5%
H: 4.61%
C: -3.32%
pharmaceuticals acquire for proposal
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
Published: 2024-04-02 (Crawled : 23:00) - biospace.com/
VNDA | $5.17 4.02% 1.8M
|
Health Technology
|
| O: -2.43%
H: 0.0%
C: -2.74%
fanapt fda approval treatment
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
Published: 2024-03-06 (Crawled : 12:00) - prnewswire.com
VNDA | $5.17 4.02% 1.8M
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: -4.4%
hetlioz fda update treatment pharmaceuticals
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-07 (Crawled : 21:00) - prnewswire.com
FNCTF | News | $11.0354 320
|
Communications
|
| O: -2.28%
H: 0.0%
C: 0.0%
JNJ | News | $147.895 1.48% 5.8M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
VNDA | $5.17 4.02% 1.8M
|
Health Technology
|
| O: 0.27%
H: 20.82%
C: 11.51%
year pharmaceuticals financial results
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
Published: 2024-01-31 (Crawled : 14:30) - biospace.com/
VNDA | $5.17 4.02% 1.8M
|
Health Technology
|
| O: 1.37%
H: 1.35%
C: -2.7%
vtr-297 fda drug candidate approval treatment pharmaceuticals antifungal
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
Published: 2024-01-30 (Crawled : 00:00) - prnewswire.com
VNDA | $5.17 4.02% 1.8M
|
Health Technology
|
| O: 0.0%
H: 0.26%
C: -3.95%
fda resolve
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
Published: 2024-01-26 (Crawled : 04:00) - prnewswire.com
JNJ | News | $147.895 1.48% 5.8M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
VNDA | $5.17 4.02% 1.8M
|
Health Technology
|
| O: 0.79%
H: 1.05%
C: -1.83%
ponvory patent pharmaceuticals
Vanda Pharmaceuticals announces the publication of an article on The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -1.0%
H: 0.84%
C: 0.04%
VNDA | $5.17 4.02% 1.8M
|
Health Technology
|
| O: 2.72%
H: 0.53%
C: 0.53%
publication pharmaceuticals trial diabetic
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
Published: 2024-01-23 (Crawled : 15:30) - biospace.com/
VNDA | $5.17 4.02% 1.8M
|
Health Technology
|
| O: 2.11%
H: 1.03%
C: -4.13%
vca-894 fda drug candidate approval treatment pharmaceuticals
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 70% | 30% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Last 48 Hours Insiders Buying
CLSD | $1.42 7.58% 170K
|
Health Technology
|
14:00
CDZI P 25000 | $2.255 0.22% 160K
|
Utilities
|
14:00
ETST P 39000 | $0.068 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.91 3.38% 13K
|
Finance
|
12:30
ADMQ | $0.0532 480K
|
|
10:30
AXR P 2400 | $20.99 -5.32% 11K
|
Finance
|
21:00
QCRH P 118 | $56.88 2.65% 23K
|
Finance
|
18:01
VUZI P 7500 | $1.225 -2.78% 410K
|
Electronic Technology
|
18:00
RMCF | $3.69 3.94% 9.5K
|
Consumer Non-Durables
|
20:10